Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H17NO3 |
| Molecular Weight | 199.2469 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCC1(CO)N2CCC(CC2)C1=O
InChI
InChIKey=BGBNULCRKBVAKL-UHFFFAOYSA-N
InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3
| Molecular Formula | C10H17NO3 |
| Molecular Weight | 199.2469 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:04:33 UTC 2023
by
admin
on
Sat Dec 16 10:04:33 UTC 2023
|
| Record UNII |
Z41TGB4080
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
797420
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
||
|
FDA ORPHAN DRUG |
673518
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID401164013
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
11387
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
DB11684
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
5291-32-7
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
JK-178
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
Z41TGB4080
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
52918385
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
EU/3/10/742(POSITIVE)
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | On 10 June 2010, orphan designation (EU/3/10/742) was granted by the European Commission to Aprea AB, Sweden, for 2-methoxymethyl-2-hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one (also known as APR-246) for the treatment of acute myeloid leukaemia. In March 2017, Aprea AB changed name to Aprea Therapeutics AB. | ||
|
100000175505
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
C85465
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | |||
|
EU/3/14/1386(POSITIVE)
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY | On 16 December 2014, orphan designation (EU/3/14/1386) was granted by the European Commission to Aprea AB, Sweden, for 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one (also known as APR-246) for the treatment of ovarian cancer. In March 2017, Aprea AB changed name to Aprea Therapeutics AB. | ||
|
SUB189874
Created by
admin on Sat Dec 16 10:04:33 UTC 2023 , Edited by admin on Sat Dec 16 10:04:33 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ENANTIOMER -> RACEMATE |
|
||
|
TARGET -> ACTIVATOR |
|
||
|
ENANTIOMER -> RACEMATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
